Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients
Matthew J Fisher, Luis A Marcos Raymundo, Melinda Monteforte, Erin M Taub, Roderick Go
doi:10.1016/j.ijid.2020.12.0211201-9712/
Objectives: The purpose of this study is to evaluate clinical outcomes in patients with critical COVID-19 pneumonia requiring invasive mechanical ventilation who were treated with tocilizumab Design: Single-center retrospective cohort study Setting: Stony Brook University Hospital, a 600-bed academic tertiary medical center in Suffolk County, New York Participants: Consecutive patients with COVID-19 confirmed by nasopharyngeal polymerase chain reaction (PCR) who were admitted to Stony Brook University Hospital between March 10 and April 2 2020 and required mechanical ventilation in any intensive care unit during their hospitalization Exposure: Treatment with tocilizumab while intubated Main Outcome: Overall mortality 30 days from the date of intubation Results: Forty-five patients received tocilizumab compared to seventy controls. Baseline demographic characteristics, inflammatory markers, treatment with corticosteroids, and sequential organ failure assessment (SOFA) scores were similar between the two cohorts. Patients who received tocilizumab had significantly lower Charlson co-morbidity index (2.0 vs 3.0,P = 0.01) than controls. There was a trend towards younger mean age in the tocilizumab exposed group (56.2 vs 60.6; P = 0.09). In logistic regression analysis there was no reduction in mortality associated with receipt of tocilizumab (odds ratio (OR) 1.04; 95% CI, 0.27-3.75). There was no observed increased risk of secondary infection in patients given tocilizumab (28.9 vs 25.7; OR 1.17; 95% CI, 0.51-2.71). Conclusion: When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with reduction in mortality in this retrospective cohort study of mechanically ventilated patients with COVID-19 pneumonia. Further studies are needed to determine the role of tocilizumab in the treatment of COVID-19.
Declaration of interest The authors declare no conflicts of interest.
Appendix A. Supplementary data Supplementary material related to this article can be found, in the online version, at doi: https://doi.org/10.1016/j.ijid.2020.12.021 .
References
Biran, Ip, Ahn, Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study, Lancet Rheumatol,
doi:10.1016/S2665-9913(20)30277-0Chen, Wu, Guo, Clinical and Immunologic Features of Severe and Moderate Coronavirus Disease 2019, J Clin Invest,
doi:10.1172/JCI137244Fisher, Marcos Raymundo, Monteforte, None, International Journal of Infectious Diseases
Group, Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med,
doi:10.1056/NEJMoa2021436Ruan, Yang, Wang, Jiang, Song, Clinical Predictors of Mortality due to COVID-19 Based on an Analysis of Data of 150 Patients from Wuhan China, Intensive Care Med,
doi:10.1007/s00134-020-05991-xSinha, Mostaghim, Bielick, Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge [published online ahead of print, Int J Infect Dis
Somers, Eschenauer, Troost, Tocilizumab for treatment of mechanically ventilated patients with COVID-19, Clin Infect Dis,
doi:10.1093/cid/ciaa954Zhang, Wu, Li, Zhao, Wang, The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105954DOI record:
{
"DOI": "10.1016/j.ijid.2020.12.021",
"ISSN": [
"1201-9712"
],
"URL": "http://dx.doi.org/10.1016/j.ijid.2020.12.021",
"alternative-id": [
"S1201971220325443"
],
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "International Journal of Infectious Diseases"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.ijid.2020.12.021"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases."
}
],
"author": [
{
"affiliation": [],
"family": "Fisher",
"given": "Matthew J.",
"sequence": "first"
},
{
"affiliation": [],
"family": "Marcos Raymundo",
"given": "Luis A.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Monteforte",
"given": "Melinda",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Taub",
"given": "Erin M.",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Go",
"given": "Roderick",
"sequence": "additional"
}
],
"container-title": "International Journal of Infectious Diseases",
"container-title-short": "International Journal of Infectious Diseases",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"clinicalkey.fr",
"clinicalkey.jp",
"clinicalkey.es",
"clinicalkey.com.au",
"clinicalkey.com",
"ijidonline.com",
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2020,
12,
16
]
],
"date-time": "2020-12-16T10:39:19Z",
"timestamp": 1608115159000
},
"deposited": {
"date-parts": [
[
2023,
6,
30
]
],
"date-time": "2023-06-30T16:04:27Z",
"timestamp": 1688141067000
},
"indexed": {
"date-parts": [
[
2024,
7,
15
]
],
"date-time": "2024-07-15T00:12:49Z",
"timestamp": 1721002369487
},
"is-referenced-by-count": 18,
"issued": {
"date-parts": [
[
2021,
2
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
2,
1
]
],
"date-time": "2021-02-01T00:00:00Z",
"timestamp": 1612137600000
}
},
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
12,
10
]
],
"date-time": "2020-12-10T00:00:00Z",
"timestamp": 1607558400000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S1201971220325443?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S1201971220325443?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "536-539",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2021,
2
]
]
},
"published-print": {
"date-parts": [
[
2021,
2
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"article-title": "Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study [published online ahead of print, 2020 Aug 14]",
"author": "Biran",
"journal-title": "Lancet Rheumatol",
"key": "10.1016/j.ijid.2020.12.021_bib0005",
"year": "2020"
},
{
"DOI": "10.1172/JCI137244",
"article-title": "Clinical and Immunologic Features of Severe and Moderate Coronavirus Disease 2019",
"author": "Chen",
"doi-asserted-by": "crossref",
"journal-title": "J Clin Invest",
"key": "10.1016/j.ijid.2020.12.021_bib0010",
"year": "2020"
},
{
"article-title": "Use of Siltuximab In Patients with Covid-19 Pneumonia Requiring Ventilatory Support",
"author": "Gritti",
"journal-title": "medRxiv",
"key": "10.1016/j.ijid.2020.12.021_bib0015",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2002032",
"article-title": "Clinical Characteristics of Coronavirus Disease 2019 in China",
"author": "Guan",
"doi-asserted-by": "crossref",
"first-page": "1708",
"issue": "18",
"journal-title": "N Engl J Med",
"key": "10.1016/j.ijid.2020.12.021_bib0020",
"volume": "382",
"year": "2020"
},
{
"article-title": "Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report [published online ahead of print, 2020 Jul 17]",
"author": "RECOVERY Collaborative Group",
"journal-title": "N Engl J Med",
"key": "10.1016/j.ijid.2020.12.021_bib0025",
"year": "2020"
},
{
"article-title": "Interleukin-6 blockade for severe COVID-19",
"author": "Roumier",
"journal-title": "medRxiv",
"key": "10.1016/j.ijid.2020.12.021_bib0030",
"year": "2020"
},
{
"DOI": "10.1007/s00134-020-05991-x",
"article-title": "Clinical Predictors of Mortality due to COVID-19 Based on an Analysis of Data of 150 Patients from Wuhan China",
"author": "Ruan",
"doi-asserted-by": "crossref",
"first-page": "846",
"issue": "5",
"journal-title": "Intensive Care Med",
"key": "10.1016/j.ijid.2020.12.021_bib0035",
"volume": "46",
"year": "2020"
},
{
"DOI": "10.1016/j.ijid.2020.07.023",
"article-title": "Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge [published online ahead of print, 2020 Jul 25]",
"author": "Sinha",
"doi-asserted-by": "crossref",
"first-page": "28",
"journal-title": "Int J Infect Dis",
"key": "10.1016/j.ijid.2020.12.021_bib0040",
"volume": "99",
"year": "2020"
},
{
"article-title": "Tocilizumab for treatment of mechanically ventilated patients with COVID-19 [published online ahead of print, 2020 Jul 11]",
"author": "Somers",
"journal-title": "Clin Infect Dis",
"key": "10.1016/j.ijid.2020.12.021_bib0045",
"year": "2020"
},
{
"DOI": "10.1073/pnas.2005615117",
"article-title": "Effective Treatment of Severe COVID-19 patients with Tocilizumab",
"author": "Xu",
"doi-asserted-by": "crossref",
"journal-title": "Proc Natl Acad Sci U S A.",
"key": "10.1016/j.ijid.2020.12.021_bib0050",
"year": "2020"
},
{
"DOI": "10.1016/j.jinf.2020.03.037",
"article-title": "The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19",
"author": "Ye",
"doi-asserted-by": "crossref",
"first-page": "607",
"issue": "6",
"journal-title": "J Infect",
"key": "10.1016/j.ijid.2020.12.021_bib0055",
"volume": "80",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105954",
"article-title": "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality",
"author": "Zhang",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.ijid.2020.12.021_bib0060",
"year": "2020"
}
],
"reference-count": 12,
"references-count": 12,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S1201971220325443"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"special_numbering": "C",
"subject": [],
"subtitle": [],
"title": "Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy",
"volume": "103"
}
